Griffin Asset Management’s Summit Therapeutics SMMT Stock Holding History

Griffin Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.82M	Buy	193,582 +1,710	+0.9%	+$30.3K	0.3%	77
2026 Q1	$3.64M	Sell	191,872 -3,675	-2%	-$59.4K	0.41%	67
2025 Q4	$3.42M	Buy	195,547 +55,265	+39%	+$1.04M	0.37%	70
2025 Q3	$2.9M	Buy	140,282 +20,900	+18%	+$507K	0.33%	77
2025 Q2	$2.54M	Buy	119,382 +2,172	+2%	+$49.5K	0.3%	86
2025 Q1	$2.26M	Buy	117,210 +6,550	+6%	+$131K	0.28%	90
2024 Q4	$1.97M	Buy	110,660 +42,900	+63%	+$832K	0.23%	93
2024 Q3	$1.48M	Buy	+67,760	New	+$948K	0.17%	111

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Griffin Asset Management's SMMT Position: Q2 2026 in Review

Griffin Asset Management increased its Summit Therapeutics (SMMT) stake by 0.89% in Q2 2026, buying an estimated $30.3K and bringing the position to 193,582 shares worth $2.82M. The position accounts for 0.3% of the portfolio, ranked #77.

Griffin Asset Management first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.64M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Griffin Asset Management held 193,582 shares of Summit Therapeutics worth $2.82M as of Q2 2026.
Griffin Asset Management bought 1,710 Summit Therapeutics shares in Q2 2026, an estimated $30.3K.
Summit Therapeutics made up 0.3% of Griffin Asset Management's portfolio in Q2 2026, its #77 holding.
Griffin Asset Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Griffin Asset Management's Summit Therapeutics position peaked at $3.64M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Griffin Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.